MBX Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost
MBX Biosciences, Inc. (MBX) had Debt Securities, Available-for-sale, Amortized Cost of $365.68 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $365.68M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $395.37M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $298.13M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $168.39M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $365.68M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $395.37M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $298.13M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $168.39M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $186.36M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $211.58M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $222.73M 10-K · filed 2026-03-12 |
| 2023-12-31 | $50.09M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |